Hamdy Osama, Mottalib Adham, Morsi Amr, El-Sayed Nuha, Goebel-Fabbri Ann, Arathuzik Gillian, Shahar Jacqueline, Kirpitch Amanda, Zrebiec John
Joslin Diabetes Center, Harvard Medical School , Boston, Massachusetts , USA.
BMJ Open Diabetes Res Care. 2017 Jan 4;5(1):e000259. doi: 10.1136/bmjdrc-2016-000259. eCollection 2017.
We evaluated long-term impact of sustained weight loss versus weight regain on cardiovascular risk factors in real-world clinical practice.
We evaluated 129 obese patients with diabetes enrolled in Weight Achievement and Intensive Treatment (Why WAIT) program, a 12-week clinical model of intensive lifestyle intervention. After 1 year, we divided participants into group A, who maintained <7% weight loss (47.3%) and group B (52.7%), who maintained ≥7% weight loss. We continued to follow them for a total of 5 years.
The total cohort lost 23.8 lbs (-9.7%) at 12 weeks and maintained -16.2 lbs (-6.4%) at 5 years (p<0.001). Group A maintained -8.4 lbs (-3.5%) and group B maintained -23.1 lbs (-9.0%) at 5 years. In group A, A1C decreased from 7.5±1.3% to 6.7±0.9% at 12 weeks but increased to 7.7±1.4% at 1 year and 8.0±1.9% at 5 years. In group B, A1C decreased from 7.4±1.2% to 6.4±0.9% at 12 weeks and rose to 6.8±1.2% at 1 year and 7.3±1.5% at 5 years. Despite weight regain, group A maintained improvement in low-density lipoprotein-cholesterol and high-density lipoprotein-cholesterol with worsening of serum triglycerides and no change in blood pressure (BP). Group B maintained improvement in lipid profile for 5 years and had significantly lower BP for 18 months.
Weight reduction in patients with diabetes can be maintained for 5 years and is predicted by patients' ability to maintain ≥7% weight loss at 1 year. A1C and triglycerides deteriorate with weight regain, while other lipid improvements are maintained. Sustained weight loss is associated with significantly lower A1C for 5 years and lowers BP for 18 months.
NCT01937845.
我们评估了在现实临床实践中持续减重与体重反弹对心血管危险因素的长期影响。
我们评估了129名参加体重实现与强化治疗(为何等待)项目的肥胖糖尿病患者,该项目是一个为期12周的强化生活方式干预临床模式。1年后,我们将参与者分为A组,体重减轻<7%(47.3%),以及B组(52.7%),体重减轻≥7%。我们继续对他们进行了总共5年的随访。
整个队列在12周时体重减轻了23.8磅(-9.7%),在5年时维持在-16.2磅(-6.4%)(p<0.001)。A组在5年时维持减重-8.4磅(-3.5%),B组在5年时维持减重-23.1磅(-9.0%)。在A组中,糖化血红蛋白(A1C)在12周时从7.5±1.3%降至6.7±0.9%,但在1年时升至7.7±1.4%,在5年时升至8.0±1.9%。在B组中,A1C在12周时从7.4±1.2%降至6.4±0.9%,在1年时升至6.8±1.2%,在5年时升至7.3±1.5%。尽管体重反弹,但A组低密度脂蛋白胆固醇和高密度脂蛋白胆固醇仍保持改善,血清甘油三酯恶化,血压(BP)无变化。B组脂质谱改善维持了5年,血压在18个月内显著降低。
糖尿病患者的体重减轻可维持5年,且可通过患者在1年时维持≥7%体重减轻的能力来预测。随着体重反弹,A1C和甘油三酯恶化,而其他脂质改善得以维持。持续减重与5年内显著降低的A1C相关,并在18个月内降低血压。
NCT01937845。